Literature DB >> 25085446

No change of the lipid profile under the control of ApoE gene polymorphism in schizophrenics under paliperidone treatment.

Wei-Tsung Kao1, Chen-Lin Chang, Yi-Lung Chen, For-Wey Lung.   

Abstract

The present study tried to explore the effects of Paliperidone on the lipid profiles of schizophrenia patients. One hundred twenty-nine subjects diagnosed with schizophrenia were enrolled into this study and completed the lipid profile evaluation. Their blood samples were obtained on the morning following a 12-hours fast. Cholesterol and triglyceride (TG) levels in plasma were determined, and lipoproteins were determined by enzymatic methods. All participants provided written informed consent, and underwent additional venous blood withdrawal for DNA extraction for genetic study of the ApoE gene polymorphism. Under T test, TC, TG and HDL levels all declined after Paliperidone treatment although with no statistically significant difference. The ratios of TC/HDL declined after Paliperidone treatment, but without statistically significant difference. After GEE-I analysis, we found that ApoE4 genotype (β = 34.471; p < 0.001) had a positive effect on the total cholesterol (TC) level; female had positive effect on the high-density lipoprotein (HDL) level (β = 15.361; p = 0.003); and age had a positive effect on the TG level (β = 1.317; p = 0.030). Smoking (β = 0.961; p = 0.016) had a positive effect on the ratio of TC/HDL change. Lipid profiles were not increased after Paliperidone treatment under the control of ApoE gene polymorphism.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25085446     DOI: 10.1007/s11126-014-9309-3

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  53 in total

1.  Apolipoprotein E polymorphism and serum lipid response to plant sterols in humans.

Authors:  A Geelen; P L Zock; J H M de Vries; M B Katan
Journal:  Eur J Clin Invest       Date:  2002-10       Impact factor: 4.686

2.  Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism.

Authors:  E Boerwinkle; G Utermann
Journal:  Am J Hum Genet       Date:  1988-01       Impact factor: 11.025

3.  Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.

Authors:  Yinbo Zhang; Guangzhi Dai
Journal:  Hum Psychopharmacol       Date:  2012-11       Impact factor: 1.672

4.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

Review 5.  Review of atypical antipsychotics and weight gain.

Authors:  N Sussman
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

6.  Obesity and alcohol modulate the effect of apolipoprotein E polymorphism on lipids and insulin.

Authors:  Pedro Marques-Vidal; Vanina Bongard; Jean-Bernard Ruidavets; Josette Fauvel; Hélène Hanaire-Broutin; Bertrand Perret; Jean Ferrières
Journal:  Obes Res       Date:  2003-10

7.  Metabolic syndrome in patients with schizophrenia.

Authors:  Tuula Heiskanen; Leo Niskanen; Riitta Lyytikäinen; Pirjo I Saarinen; Jukka Hintikka
Journal:  J Clin Psychiatry       Date:  2003-05       Impact factor: 4.384

8.  Epsilon 4 allele of apolipoprotein E gene associates with lower blood pressure in young Japanese subjects: the Suita Study.

Authors:  Tomohiro Katsuya; Shunroku Baba; Kazuhiko Ishikawa; Toshifumi Mannami; Yuxiao Fu; Nozomu Inamoto; Takashi Asai; Masayuki Fukuda; Jitsuo Higaki; Jun Ogata; Toshio Ogihara
Journal:  J Hypertens       Date:  2002-10       Impact factor: 4.844

9.  ApoE polymorphism in a small Mediterranean island: relationships with plasma lipids, lipoproteins and LDL particle size.

Authors:  C M Barbagallo; F Polizzi; M Severino; M Rizzo; N Vivona; F Onorato; R Caldarella; A B Cefalù; D Noto; A Notarbartolo; M R Averna
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

Review 10.  Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases.

Authors:  Kathleen S Montine; Joseph F Quinn; Jing Zhang; Joshua P Fessel; L Jackson Roberts; Jason D Morrow; Thomas J Montine
Journal:  Chem Phys Lipids       Date:  2004-03       Impact factor: 3.329

View more
  1 in total

1.  Cardiovascular Pharmacogenomics and Cognitive Function in Patients with Schizophrenia.

Authors:  Kristen M Ward; A Zarina Kraal; Stephanie A Flowers; Vicki L Ellingrod
Journal:  Pharmacotherapy       Date:  2017-08-02       Impact factor: 4.705

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.